大麻和阿尔茨海默病:全面的审查和分子相互作用的洞察力
João V Mello-Hortega1, Carolina S de Oliveira1, Vitoria S de Araujo1
1Polymorphisms and Linkage Laboratory, Postgraduate Program in Genetics, Department of Genetics, Federal University of Paraná (UFPR), Curitiba, Paraná, Brazil.
The European journal of neuroscience
|August 27, 2025
概括
大麻二醇 (CBD) 是阿尔茨海默病 (AD) 补充治疗的有望药物,有可能缓解粉样质斑块,酸化和神经炎症. 需要进一步研究CBD的治疗机制和基因标.
科学领域:
- 神经科学
- 药理学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其原因复杂,包括粉样斑块,病理,神经炎症和氧化应激.
- 目前使用的抗胆酶药物具有局限性和副作用,促使研究替代疗法.
研究的目的:
- 综合有关大麻醇 (CBD) 对阿尔茨海默病 (AD) 的治疗效果的现有证据.
- 研究CBD对AD的主要病理特征和生理途径的影响.
- 在AD中使用in silico分析确定CBD作用机制的潜在基因标.
主要方法:
- 关于CBD和AD研究的综合文献审查.
- 对CBD对粉样层级,陶酸化,神经炎症,氧化应激,胆固醇通路,新陈代谢和行为的影响的分析.
- 在基因表达数据的分析中,绘制与CBD相关的网络和途径.
主要成果:
- 在AD中,CBD具有调节氨基酸级联,陶酸化,神经炎症和氧化应激的潜力.
- 有证据表明,CBD可能会影响胆固醇通路,葡萄糖/脂质代谢以及与AD相关的行为症状.
- 在分析中确定了CBD在AD治疗作用的潜在基因网络和生物途径.
结论:
- 大麻 (CBD) 是阿尔茨海默病 (AD) 的一个有前途的补充治疗策略.
- CBD的多方面行动针对阿尔茨海默病的关键病理特征和生理功能障碍.
- 对已识别的基因标进行进一步的研究可以加深对基于CBD的AD疗法的理解和优化.
相关概念视频
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260


